NASDAQ:RDHL RedHill Biopharma (RDHL) Stock Price, News & Analysis → Did you make $29,000 two days with AI options trades? (From Prosper Trading Academy) (Ad) Free RDHL Stock Alerts $0.52 +0.01 (+2.30%) (As of 12:08 PM ET) Add Compare Share Share Today's Range$0.50▼$0.5550-Day Range$0.46▼$1.0852-Week Range$0.26▼$4.92Volume356,608 shsAverage Volume1.32 million shsMarket Capitalization$15.56 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get RedHill Biopharma alerts: Email Address Ad Prosper Trading AcademyDid you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:Click Here To Get Your Free Copy About RedHill Biopharma Stock (NASDAQ:RDHL)RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; and RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.Read More RDHL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RDHL Stock News HeadlinesMarch 21, 2024 | americanbankingnews.comRedHill Biopharma (NASDAQ:RDHL) Stock Price Crosses Below Two Hundred Day Moving Average of $0.78March 11, 2024 | markets.businessinsider.comRedHill Biopharma Receives New Patent For H. Pylori Treatment TaliciaMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 11, 2024 | finance.yahoo.comRedHill Announces New USPTO Patent Covering Talicia® Through 2034March 5, 2024 | finance.yahoo.comRedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures ProgramsFebruary 20, 2024 | finance.yahoo.comRedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New PublicationFebruary 20, 2024 | prnewswire.comRedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New PublicationFebruary 16, 2024 | barrons.comRedHill Biopharma Ltd. ADRMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.January 26, 2024 | finance.yahoo.comRedHill Biopharma Announces Closing of $8 Million Registered Direct OfferingJanuary 25, 2024 | msn.comRedHill gains after new patent grant for Talicia for H. pylori treatment through 2042January 25, 2024 | finance.yahoo.comRedHill Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042January 25, 2024 | finance.yahoo.comRedHill Biopharma Announces $8 Million Registered Direct OfferingJanuary 24, 2024 | benzinga.comWhy Redhill Biopharma Stock Is Moving HigherDecember 20, 2023 | msn.comRedHill's Investigational COVID-19 Drugs Combined With Gilead's Show Effect Against EbolaDecember 20, 2023 | markets.businessinsider.comRedHill Announces Results Of A New U.S. Army-funded In Vivo Ebola Virus StudyDecember 20, 2023 | msn.comRedHill shares rally 20% on positive data for two antiviral drugsDecember 20, 2023 | finance.yahoo.comRedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against EbolaDecember 12, 2023 | msn.comRedHill Biopharma regains compliance with Nasdaq listing ruleDecember 4, 2023 | finance.yahoo.comRedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 StudyNovember 30, 2023 | benzinga.comRedhill Biopharma Stock (NASDAQ:RDHL), Short Interest ReportNovember 29, 2023 | msn.comWhat's Going On With Redhill Biopharma Stock?November 27, 2023 | investorplace.com5 Investors Betting Big on RedHill Biopharma (RDHL) StockNovember 27, 2023 | msn.comWhy Is Gastrointestinal Disease Focused-RedHill Biopharma Stock Higher Over 100% Today?November 27, 2023 | markets.businessinsider.comRedHill's Talicia Granted 5-year Market Exclusivity By FDANovember 27, 2023 | finance.yahoo.comRedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia® with IP Protection Running to 2034November 22, 2023 | finance.yahoo.comRedHill Biopharma Announces the Transfer of its Listing to The Nasdaq Capital MarketSee More Headlines Receive RDHL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RedHill Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/30/2021Today3/28/2024Next Earnings (Estimated)4/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RDHL CUSIPN/A CIK1553846 Webwww.redhillbio.com Phone972-3541-3131Fax972-3541-3144Employees113Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-71,670,000.00 Net Margins354.95% Pretax MarginN/A Return on Equity-328.99% Return on Assets71.39% Debt Debt-to-Equity RatioN/A Current Ratio0.96 Quick Ratio0.78 Sales & Book Value Annual Sales$61.80 million Price / Sales0.25 Cash FlowN/A Price / Cash FlowN/A Book Value($16.41) per share Price / Book-0.03Miscellaneous Outstanding Shares29,700,000Free Float27,680,000Market Cap$15.74 million OptionableNo Data Beta3.48 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Dror Ben-Asher (Age 58)Co-Founder, Chairman & CEO Comp: $594.61kMr. Razi Ingber (Age 40)Chief Financial Officer Comp: $339.82kMr. Gilead Raday MPhil (Age 49)MSc, Chief Operating Officer Comp: $365.56kMr. Adi Frish (Age 54)Chief Corporate & Business Development Officer Comp: $339.3kMr. Rick D. Scruggs (Age 64)Chief Commercial Officer, President of RedHill Biopharma Inc. & Director Comp: $469.8kMs. Alexandra OkmianSenior Business Development & Investor Relations ManagerDr. Reza Fathi Ph.D. (Age 69)Senior Vice President of Research & Development Comp: $299.29kMr. Guy Goldberg J.D. (Age 48)Chief Business Officer Comp: $338.13kDr. June S. Almenoff FACP (Age 67)M.D., Ph.D., Chief Medical Officer Ms. Patricia Anderson B.Sc. RACSenior Vice President of Regulatory AffairsMore ExecutivesKey CompetitorsRenovoRxNASDAQ:RNXTVBI VaccinesNASDAQ:VBIVABVC BioPharmaNASDAQ:ABVCCocrystal PharmaNASDAQ:COCPNanoViricidesNYSE:NNVCView All Competitors RDHL Stock Analysis - Frequently Asked Questions How have RDHL shares performed in 2024? RedHill Biopharma's stock was trading at $1.46 at the beginning of the year. Since then, RDHL stock has decreased by 64.1% and is now trading at $0.5239. View the best growth stocks for 2024 here. Are investors shorting RedHill Biopharma? RedHill Biopharma saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 1,060,000 shares, an increase of 181.8% from the February 29th total of 376,200 shares. Based on an average trading volume of 1,370,000 shares, the days-to-cover ratio is currently 0.8 days. Approximately 3.6% of the company's stock are short sold. View RedHill Biopharma's Short Interest. When is RedHill Biopharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, April 26th 2024. View our RDHL earnings forecast. How were RedHill Biopharma's earnings last quarter? RedHill Biopharma Ltd. (NASDAQ:RDHL) announced its earnings results on Tuesday, November, 30th. The biotechnology company reported ($20.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($19.20) by $0.80. The biotechnology company earned $21.61 million during the quarter, compared to analyst estimates of $23.41 million. RedHill Biopharma had a net margin of 354.95% and a negative trailing twelve-month return on equity of 328.99%. During the same quarter last year, the business earned ($20.00) earnings per share. When did RedHill Biopharma's stock split? RedHill Biopharma's stock reverse split on the morning of Thursday, March 23rd 2023. The 1-40 reverse split was announced on Thursday, March 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, March 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of RedHill Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other RedHill Biopharma investors own include Agenus (AGEN), Sorrento Therapeutics (SRNE), Sangamo Therapeutics (SGMO), Verastem (VSTM), Amarin (AMRN), Aralez Pharmaceuticals (ARLZ), Inovio Pharmaceuticals (INO), Tesla (TSLA), Gilead Sciences (GILD) and NVIDIA (NVDA). Who are RedHill Biopharma's major shareholders? RedHill Biopharma's stock is owned by a variety of retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of RedHill Biopharma? Shares of RDHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RDHL) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RedHill Biopharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.